A strong consensus (89.2%) supported a broader, multidimensional definition of HE-DMTs [2, 3, 6], incorporating not only a substantial suppression of relapses (≥45–50% ARR reduction) and MRI activity (≥80% reduction in new/enlarging T2-hyperintense WM or Gd-enhancing lesions), but also effects on disability progression, brain/spinal cord atrophy, fluid biomarkers such as NfL, and PROs. Here, NEFL is linked to hereditary elliptocytosis.